Labcorp Holdings Inc.
LH$314.22
+$1.88 (0.60%)+0.60%
OpenLabcorp announces nationwide launch of Roche’s FDA-approved VENTANA PTEN (SP218) companion diagnostic assay for prostate cancer across its U.S. laboratory network.
Loading chart...
IndexN/A
Market Cap25.77B
Enterprise Value27.54B
Income$0.21B
Sales$3.35B
Employees60,900
P/E18.65
P/S1.50
P/B2.42
P/C17.31
EV/EBITDA13.69
EV/Sales8.36
EPS (ttm)16.85
Earnings2025-10-28
Gross Margin28.34%
Oper. Margin9.75%
Profit Margin6.36%
Volume0.17M
Shs Outstand0.08B
Change0.60%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTD7.63%
Perf Year13.54%
Perf 3Y23.76%
Perf 5Y39.67%
Perf 10Y186.82%
IPO1990-03-29
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.01B | $12.16B | $11.86B | $13.14B | $13.98B | $11.55B | $11.33B | $10.44B |
| Cost of Revenue | $9.38B | $8.80B | $8.15B | $8.14B | $9.03B | $8.30B | $8.16B | $6.98B |
| Gross Profit | $3.62B | $3.36B | $3.71B | $4.99B | $4.95B | $3.25B | $3.18B | $3.46B |
| Gross Margin | 27.86% | 27.67% | 31.26% | 38.01% | 35.43% | 28.15% | 28.03% | 33.18% |
| Operating Expenses | $2.54B | $2.64B | $2.27B | $1.94B | $2.51B | $1.92B | $1.85B | $2.10B |
| Operating Income | $1.09B | $725.60M | $1.44B | $3.05B | $2.45B | $1.33B | $1.33B | $1.36B |
| Operating Margin | 8.35% | 5.97% | 12.11% | 23.21% | 17.49% | 11.51% | 11.70% | 13.07% |
| Net Income | $746.00M | $418.00M | $1.28B | $2.38B | $1.56B | $823.80M | $883.70M | $1.27B |
| Net Margin | 5.73% | 3.44% | 10.78% | 18.10% | 11.13% | 7.13% | 7.80% | 12.15% |
| EPS (Basic) | $8.89 | $4.80 | $14.04 | $24.58 | $15.99 | $8.41 | $8.71 | $12.39 |
| EBITDA | $1.81B | $1.35B | $1.95B | $3.68B | $3.25B | $2.12B | $2.06B | $1.85B |
| Stock Option Compensation Expense | $116.70M | $128.70M | $116.80M | $132.90M | $111.70M | $107.00M | $91.60M | $109.70M |
| Price To Earnings Ratio | 25.79 | 47.36 | 14.41 | 10.98 | 10.93 | 17.27 | 12.46 | 11.06 |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | $19.24B | $19.80B | $18.43B | $26.10B | $17.01B | $14.23B | $11.01B | $14.03B |
Company coverage
Latest news
Here's Why Labcorp Holdings (LH) is a Strong Value Stockzacks.com Labcorp Launches FDA-Approved PTEN Companion Diagnostic for Prostate Cancerprnewswire.com Labcorp Q2 Earnings Call Highlightsmarketbeat.com Labcorp Holdings Inc. (LH) Q2 2026 Earnings Call Transcriptseekingalpha.com LH Stock Down Despite Q2 Earnings and Revenue Beat, Margins Risezacks.com Labcorp (LH) Reports Q2 Earnings: What Key Metrics Have to Sayzacks.com Labcorp Holdings (LH) Surpasses Q2 Earnings and Revenue Estimateszacks.com Labcorp raises annual profit forecast on strong testing demandreuters.com
Show 12 more stories
Labcorp Announces 2026 Second Quarter Results; Raises Full Year 2026 Guidanceprnewswire.com Labcorp (LH) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimateszacks.com Labcorp Launches Marker by Labcorp™ Genetic Health Panel, Expanding Consumer Access to Hereditary Genetic Risk Testingprnewswire.com Labcorp Holdings Inc. (LH) Hit a 52 Week High, Can the Run Continue?zacks.com Strength Seen in Labcorp (LH): Can Its 3.4% Jump Turn into More Strength?zacks.com Labcorp Holdings (LH) Earnings Expected to Grow: Should You Buy?zacks.com Labcorp Prepares to Report Q2 Earnings: What's in the Cards?zacks.com Will Labcorp (LH) Beat Estimates Again in Its Next Earnings Report?zacks.com California Public Employees Retirement System Has $52.08 Million Stock Holdings in Labcorp Holdings Inc. $LHdefenseworld.net Labcorp Holdings Inc. $LH Stock Position Raised by D.A. Davidson & CO.defenseworld.net Labcorp Holdings: The Story Has Not Changed Materiallyseekingalpha.com Why Labcorp Holdings (LH) is a Top Value Stock for the Long-Termzacks.com
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
Discover more
You may be interested in